Company intelligence / Profile preview

Wave Life Sciences

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

Wave has demonstrated first-in-class results such as allele-selective reduction of mutant huntingtin protein while sparing wild-type in HD patients. Its DMD program showed >7% mean normal dystrophin production at Phase 2 with significant functional improvements over existing therapies. The company achieved the first-ever therapeutic RNA editing in humans for AATD. An siRNA candidate targeting INHBE is entering clinical trials for obesity.

Therapeutic areas: EndocrinologyRare DiseasesNeurology
Modalities: Antisense oligonucleotideSmall interfering RNARNA therapyRNA editing therapy
Industry: Biotech

Beyond the preview

Go deeper on Wave Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wave Life Sciences.

Explore the full profile